|
市場調查報告書
驚恐症治療藥市場的新動向
R&D Update: What's on the Horizon for the Panic Disorder Market?
|
驚恐症治療藥市場的新動向 是由出版商Decision Resources, Inc.在2008年07月所出版的。
這份英文市場調查報告書包含21 Pages 價格從美金2250起跳。
本報告書內容包括：驚恐症概要、特色、風險因素、發病率與既有及新治療藥的動向調查分析、新治療藥的開發動向、已上市的治療藥銷售實績、各藥物分類的市場佔有率等。內容綱要摘要如下：
實施概要
介紹
關於驚恐症
- 疾病概要
- 診斷
- 病態生理
- 正腎上腺素
- 血清素
- Gamma 胺基定酸
- 穀氨酸鹽
- 促腎上腺皮質激素釋放因子
- 神經發炎物質P
- 預防驚恐症
現在的治療藥
- 選擇性血清素再回收抑制劑
- 雙重再回收抑制劑
- 苯環類藥物
新治療藥
- Sepracor的SEP-225441
- Alexza Pharmaceuticals的AZ-002
驚恐症市場：2007年的統計・未來預測
圖表
Abstract
Introduction
Panic disorder (PD) affects a large number of people and has a large diagnosed
and drug-treated population. Nonetheless, the pipeline for agents to treat PD
remains small, eclipsed by the development of agents for other anxiety
disorders. This dearth opens a clear opportunity for an emerging agent that
can offer superior effi cacy over the available options.
Get the Answers You Need to Shape Your Strategy
- PD can be highly debilitating, with the associated anxiety causing those
with this d ? isease to signifi cantly limit their activities. How many
people in the seven major markets we cover (the United States, France,
Germany, Italy, Spain, the United Kingdom, and Japan) have PD? What brain
structures and neurotransmitters have been implicated in the development of
PD? How is the disease diagnosed?
- A variety of drug classes are used to treat PD. What are the most
popular therapies for the treatment of PD? Does approval for the treatment of
the disease increase the likelihood it will be prescribed?
- Few agents are being developed for the treatment of PD. Why are drug
developers choosing to develop agents for anxiety orders other than PD? What
agents are currently in the pipeline for PD, and are they likely to replace
any existing agents? What changes can be expected in the PD market over the
next five years?
Scope
- Overview of PD: disease description, diagnosis, pathophysiology,
and prevalence.
- Current therapies: selective serotonin reuptake inhibitors,
serotonin and norepinephrine reuptake inhibitors, and benzodiazepines.
- Emerging therapies: challenges to developing agents for PD,
Sepracor' s SEP-225441, and Alexza Pharmaceuticals' AZ-002.
- PD market: 2007 statistics, outlook for emerging agents.
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Overview of Panic Disorder
- Disease Description
- Diagnosis
- Pathophysiology of Panic Disorder
- Norepinephrine
- Serotonin
- Gamma-Aminobutyric Acid
- Glutamate
- Corticotropin-Releasing Factor
- Substance P
- Prevalence of Panic Disorder
- Current Therapies for Panic Disorder
- Selective Serotonin Reuptake Inhibitors
- Serotonin and Norepinephrine Reuptake Inhibitors
- Benzodiazepines
- Emerging Therapies for Panic Disorder
- Sepracor' s SEP-225441
- Alexza Pharmaceuticals' AZ-002
- Panic Disorder Market: 2007 Statistics and Future Outlook
Tables
- 1. Characteristics of a Panic Attack
- 2. Risk Factors for Panic Disorder
- 3. Therapies Commonly Used to Treat Panic Disorder, 2008
- 4. Agents in Development to Treat Anxiety Disorders, 2008
- 5. Sales of Agents to Treat Panic Disorder, 2007
Figures
- 1. Structures of the Brain Implicated in Panic Disorder
- 2. Prevalent Cases of Panic Disorder in the Major Markets, 2007 and 2012
- 3. Market Share of Drug Classes Used to Treat Panic Disorder, 2007
|
